Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report), reducing the price ...
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...
FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –– Second designation received for ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative ...
With the first wave of Alzheimer’s disease drugs reaching the market, investors continue to seek out the next big advance in ...
The Food and Drug Administration (FDA) recently approved a new drug from Eli Lilly to treat Alzheimer’s disease. Called ...
After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and ...
A team of researchers at UTMB developed a drug that attacks the bad stuff in the brain that causes Alzheimer's. Now, there's ...